Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 3 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Proteins in blood could predict psoriasis response to tofacitinib, etanercept

06 May 2020
Psoriasis affecting the upper limb

Predictive models that include blood inflammatory proteins such as interleukins (IL) 17A and 17C may help gauge the clinical response of psoriasis patients to tofacitinib and etanercept, a new study has shown.

“From a precision/personalized medicine perspective, this study has further demonstrated the potential of machine-learning to predict treatment responses to well-established psoriasis treatments, and to do so using minimally invasive blood sampling,” said researchers.

From blood samples of 266 patients with moderate-to-severe chronic plaque psoriasis, researchers quantified longitudinal protein profiles of 92 inflammation-associated proteins and 65 cardiovascular disease-associated proteins. A patient was deemed to have responded to the treatment if their Psoriasis Area & Severity Index (PASI) score decreased by >75 percent after 12 weeks of treatment.

Machine-learning algorithms produced several predictive profiles for treatment response. The best model yielded a 78.4-percent accuracy for tofacitinib response, with an area under the receiver operating characteristic (AUROC) curve of 83 percent.

In comparison, the best-performing model for etanercept response had an accuracy of 77.5 percent, with an AUROC of 81 percent.

Both models consisted of inflammatory and cardiovascular disease biomarkers, such as IL-17C, IL-20, IL-12-receptorB, interferon gamma, C–C motif chemokine ligand 20 and C–X–C motif chemokine ligand 10.

Despite promising findings, the present study was conducted on a small cohort of patients and might have issues about generalizability. Further analyses on larger, more representative cohorts are needed.

Editor's Recommendations
Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 3 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.